

1 **A non-competing pair of human neutralizing antibodies block**

2 **COVID-19 virus binding to its receptor ACE2**

3 Yan Wu<sup>1,2,#,\*</sup>, Feiran Wang<sup>3,4,#</sup>, Chenguang Shen<sup>3,5,#</sup>, Weiyu Peng<sup>3,6,#</sup>, Delin Li<sup>3,5,7,#</sup>,  
4 Cheng Zhao<sup>3,8</sup>, Zhaohui Li<sup>3,9</sup>, Shihua Li<sup>3</sup>, Yuhai Bi<sup>3,10</sup>, Yang Yang<sup>5</sup>, Yuhuan Gong<sup>3,10</sup>,  
5 Haixia Xiao<sup>7</sup>, Zheng Fan<sup>3</sup>, Shuguang Tan<sup>3</sup>, Guizhen Wu<sup>11</sup>, Wenjie Tan<sup>11</sup>, Xuancheng  
6 Lu<sup>12</sup>, Changfa Fan<sup>13</sup>, Qihui Wang<sup>3</sup>, Yingxia Liu<sup>5</sup>, Chen Zhang<sup>1</sup>, Jianxun Qi<sup>3</sup>, George  
7 Fu Gao<sup>3,\*</sup>, Feng Gao<sup>7,\*</sup>, Lei Liu<sup>5,\*</sup>

8 **Affiliations:**

9 <sup>1</sup>Department of Pathogen Microbiology, School of Basic Medical Sciences, Capital  
10 Medical University, Beijing, China.

11 <sup>2</sup>Research Network of Immunity and Health (RNIH), Beijing Institutes of Life  
12 Science, Chinese Academy of Sciences, Beijing, China

13 <sup>3</sup>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of  
14 Microbiology, Chinese Academy of Sciences, Beijing, China.

15 <sup>4</sup>School of Life Sciences, University of Science and Technology of China, Hefei,  
16 Anhui 230026, China.

17 <sup>5</sup>Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's  
18 Hospital, Shenzhen 518112, China.

19 <sup>6</sup>College of Veterinary Medicine, China Agricultural University, Beijing, China.

20 <sup>7</sup>Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial  
21 Biotechnology, Chinese Academy of Sciences, Tianjin, China

22 <sup>8</sup>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China

23 <sup>9</sup>University of Chinese Academy of Sciences, Beijing 100049, China

24 <sup>10</sup>Center for Influenza Research and Early Warning, Chinese Academy of Sciences  
25 (CASCIRE), Beijing 100101, China

26 <sup>11</sup>NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and  
27 Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

28 <sup>12</sup>Laboratory Animal Center, Chinese Center for Disease Control and Prevention,  
29 Beijing, China

30 <sup>13</sup>Division of Animal Model Research, Institute for Laboratory Animal Resources,  
31 National Institutes for Food and Drug Control, Beijing, China

32

33 #These authors contributed equally.

34 \*Correspondence: wuy@biols.ac.cn (Y.W.); gaofeng@tib.cas.cn (F.G.),  
35 gaof@im.ac.cn (G.F.G.), liulei3322@aliyun.com (L.L.)

36

37 **Abstract**

38 Neutralizing antibodies could be antivirals against COVID-19 pandemics. Here, we  
39 report the isolation of four human-origin monoclonal antibodies from a convalescent  
40 patient in China. All of these isolated antibodies display neutralization abilities in vitro.  
41 Two of them (B38 and H4) block the binding between RBD and viral cellular receptor  
42 ACE2. Further competition assay indicates that B38 and H4 recognize different  
43 epitopes on the RBD, which is ideal for a virus-targeting mAb-pair to avoid immune  
44 escape in the future clinical applications. Moreover, therapeutic study on the mouse  
45 model validated that these two antibodies can reduce virus titers in the infected mouse  
46 lungs. Structure of RBD-B38 complex revealed that most residues on the epitope are  
47 overlapped with the RBD-ACE2 binding interface, which explained the blocking  
48 efficacy and neutralizing capacity. Our results highlight the promise of antibody-based  
49 therapeutics and provide the structural basis of rational vaccine design.

50 **One Sentence Summary:** A pair of human neutralizing monoclonal antibodies against  
51 COVID-19 compete cellular receptor binding but with different epitopes, and with  
52 post-exposure viral load reduction activity.

53 **Main Text:** The COVID-19 caused by the novel coronavirus COVID-19 virus has  
54 become a global health crisis. The virus has spread worldwide, causing fever, severe  
55 respiratory illness and pneumonia(1, 2). Phylogenetic analysis indicates that the  
56 emerging pathogen is closely related to several bat coronaviruses and to severe acute  
57 respiratory syndrome coronavirus (SARS-CoV)(3-5). It is worth to note that  
58 COVID-19 virus appears to be more easily transmitted from person to person(6). To

59 date, however, no specific drugs or vaccines are available so far, except for several  
60 general antiviral drugs (eg. Remdesivir and hydroxychloroquine, et al.) under clinical  
61 investigation.

62 COVID-19 virus belongs to betacoronavirus genus, in which five human infected  
63 pathogens are implicated(7, 8). Among them, SARS-CoV and Middle East respiratory  
64 syndrome coronavirus (MERS-CoV) are two highly pathogenic viruses. As with other  
65 coronaviruses, the spike glycoprotein (S) homotrimer on the COVID-19 virus surface  
66 plays an essential role in receptor binding, triggering the cell membrane fusion for virus  
67 entry. The S protein is a class I fusion protein and each S protomer consists of S1 and  
68 S2 domains(9). The receptor binding domain (RBD) locates on the S1 region(8).  
69 Previous studies revealed that COVID-19 virus infects host cells by using the same  
70 receptor ACE2 as SARS-CoV for entry(3, 10-12), and the RBD undergoes hinge-like  
71 conformational movements to engage ACE2 binding(13). Numerous neutralizing  
72 antibodies targeting RBD of either SARS-CoV or MERS have been identified(14-16).  
73 Therefore, screening the neutralizing antibodies against COVID-19 virus by using the  
74 RBD protein is the priority strategy.

75 We expressed COVID-19 virus RBD protein as a bait to isolate the specific single  
76 memory B-cells from peripheral blood mononuclear cells (PBMCs) of a convalescent  
77 COVID-19 patient. The variable regions encoding the heavy chain and light chain were  
78 amplified from single B cells, respectively, and were then cloned into pCAGGS vector  
79 with the constant region to produce IgG1 antibodies as previous described(17). 17  
80 paired B cell clones were amplified and 3 of which were identical (B5, B59 and H1). To

81 identify the binding abilities of these antibodies, the plasmids containing the paired  
82 heavy chain and light chains were co-transfected into HEK 293T cells for monoclonal  
83 antibodies (mAbs) production. The supernatants were then screened for binding to  
84 COVID-19 virus RBD by Bio-Layer Interferometry (BLI) in OctetRED96, and an  
85 irrelevant anti-SFTSV Gn antibody and a SARS-CoV specific antibody were used as  
86 controls. The supernatants from four different antibodies (B5, B38, H2 and H4) exhibit  
87 the binding abilities to COVID-19 virus RBD, but failed binding to SARS-CoV RBD  
88 (Figure S1), suggesting that the epitope between SARS-CoV and COVID-19 virus  
89 RBDs are immunologically distinct. The usage of both heavy chain ( $V_H$ ) and light  
90 chain ( $V_L$ ) variable genes are listed in Table S1.

91 We then further measured the binding kinetics using surface plasmon resonance (SPR).  
92 These four antibodies displayed various binding abilities to COVID-19 virus RBD,  
93 with  $K_d$  ranging from  $10^{-7}$  to  $10^{-9}$  M (Figure 1 A-D). H4 presented relatively higher  
94 binding affinity, with  $K_d$  of 4.48 nM, while B5 displayed relatively weaker binding  
95 affinity, with  $K_d$  of 305 nM. B38 and H2 bind to RBD, with  $K_d$  of 70.1 nM and 14.3 nM,  
96 respectively. We next studied the neutralizing activities against COVID-19 virus  
97 (BetaCoV/Shenzhen/SZTH-003/2020). All these four antibodies exhibit neutralizing  
98 activities, with  $IC_{50}$  values ranging from 0.177  $\mu$ g/ml to 1.375  $\mu$ g/ml (Figure 2). B38  
99 was the most potent antibody, followed by H4, H2 and B5. Combined with the results  
100 of the competitive binding assay, it is suggested that different mAbs may exert  
101 neutralizing activities through distinct mechanisms.

102 To evaluate the competition abilities of each antibody for blocking the binding between  
103 viral RBD and ACE2, we performed the competition assay by using BLI in  
104 OctetRED96 and a blocking assay by using fluorescence-activated cell sorting (FACS).  
105 Specifically, the streptavidin biosensors labelled with biotinylated RBD were saturated  
106 with antibodies, and then flowed through with the test antibodies in the presence of  
107 soluble ACE2. B38 and H4 showed completely competition with ACE2 for the binding  
108 to RBD. In contrast, B5 displayed partial competition, while H2 show no competition  
109 with ACE2 for the RBD binding (Figure 1 E-H). The blocking assay by FACS  
110 presented similar results. Specifically, the ACE2-EGFP proteins were presented on the  
111 cell surface by transfection of ACE2-EGFP plasmid into HEK 293T cells, and then  
112 stained with RBD-histag proteins (positive control) or the preincubated RBD-antibody  
113 mixture. Both B38 and H4 can block the binding between RBD and ACE2 (Figure1I),  
114 suggesting that the epitopes of these two antibodies locate on the RBD-ACE2 binding  
115 interface. To determine whether B38 and H4 target the same epitope, the epitope  
116 competition assay was performed with BLI. The viral RBD immobilized on the  
117 Ni-NTA sensor was first saturated with B38 IgG and flowed through B38 IgG in the  
118 presence or absence of H4 IgG, and vice versa. The result indicated that although  
119 RBD was saturated with the first antibody, the second antibody can still bind to RBD,  
120 suggesting that B38 and H4 recognize different epitopes on RBD with partial  
121 overlapping (Figure1 J-K).

122 To explore the protection efficacy of B38 and H4 against challenge with COVID-19  
123 virus *in vivo*, therapeutic study was performed. hACE2 transgenic mice were

124 administered with a single dose of 25 mg/kg of B38 or H4 12 hours after virus  
125 challenge. The results revealed that the body weight of B38 group substantially  
126 decreased and recovered at 3 days post infection (dpi) compared with PBS control  
127 group and H4 group (Figure 3A). The viral RNA copies of lung tissue were also  
128 detected at 3 dpi. The relative RNA copies change of both B38 group and H4 group  
129 were significantly lower than that of the PBS group, with a reduction of 32.8% and 26%  
130 RNA copies change of that in PBS group, respectively (Figure 3B). These results  
131 exhibit the identical trends to the neutralization abilities.

132 To further elucidate the structural basis of the neutralization mechanisms of the  
133 antibodies, we prepared both the RBD-B38 and RBD-H4 Fab complexes by  
134 incubating the two proteins *in vitro* and then purified with a gel filtration column.  
135 Consistent with the binding affinity between viral RBD and B38 or H4, the stable  
136 complex was obtained (Figure S2). We therefore determined the crystal structure of  
137 B38 Fab with the viral RBD at 1.9 Å resolution (Table S2). Three  
138 complementarity-determining regions (CDRs) on the heavy chain (HCDR) and two  
139 CDRs on the light chain (LCDR) are involved in interaction with the viral RBD  
140 (Figure 4A and B). The buried surface area of heavy chain and light chain on the  
141 epitope is 713.9 Å<sup>2</sup> and 497.7 Å<sup>2</sup>, respectively. There are 36 residues in viral RBD  
142 involved in the interaction with B38, of which 21 residues and 15 residues interact  
143 with heavy chain and light chain, respectively (Table S3 and Figure 4B). Sequence  
144 alignment indicates that only 15 of the 36 residues in the epitope (defined as residues  
145 buried by B38) are conserved between COVID-19 virus and SARS-CoV (Figure 4D,

146 4F, and S3). This explains the specific reactivity of B38. Hydrophilic interactions are  
147 the major interacting forces on the interface between B38 and viral RBD (Table S4).  
148 Further analysis of the interactions of the binding interface reveals that the 470-loop  
149 of viral RBD plays an important role in binding to B38 HCDR1 loop (Figure 4G).  
150 The conformation of 470-loop is supported by Q474. In contrast, the corresponding  
151 loop (460-loop) in SARS-RBD displays distinct conformation due to the  $\beta$ -turn  
152 formed by P462 and G464, which is unfit for HCDR1 binding. S30 and S31 form  
153 hydrogen bonds to the side chain of K458, while the corresponding residue H445 in  
154 SARS-CoV RBD loses the interactions (Figure 4G). For the residues on contacting  
155 with the HCDR2, K417 is the only different residue between two RBDs involved in  
156 the interactions. The corresponding residue V404 in the SARS-CoV RBD loses the  
157 hydrogen bond to Y52, and the conformational change of the threonine results in  
158 losing the interaction with Y58 side chain (Figure 4H). Notably, the interactions  
159 between the side chains of two residues (Y100 and D103) on the HCDR3 and  
160 COVID-19 virus RBD are mediated by water molecules (Figure 4I). Specifically, the  
161 oxygen atom on the hydroxyl group interacts with E484, F490, L492 and Q493 on  
162 RBD via two water molecules. The side chain of D103 on the HCDR3 interacts with  
163 Y489 through a water molecule. Residue R97 on the HCDR3 hydrogen bonds to the  
164 side chains of both Y489 and N487. For the corresponding residues involved in the  
165 interactions with HCDR3 in SARS-CoV RBD, four residues are not conserved (N487,  
166 Y489, P491 and L492). P469 and W476 (corresponding residues F490 and E484 in  
167 COVID-19 virus RBD) are two unconserved residues between these two RBDs. E484



168 provides a polar contact with Y100 through water molecule, while P469 and W476 in  
169 SARS-CoV RBD are hydrophobic residues, which may be unsuitable for antibody  
170 binding. By contrast, residues involved in the interactions with LCDR loops between  
171 COVID-19 virus RBD and SARS-CoV RBD are more conserved (Figure 4J and K).  
172 Although two residues involved in the binding to LCDR3 loop are different between  
173 these two RBDs, they have the same properties (R403 and E406 in COVID-19 virus  
174 RBD, the corresponding residues are K491 and D493 in SARS-CoV RBD). This  
175 perfectly explains the B38 specific binding to COVID-19 rather than SARS-CoV.  
176 To explore the structural basis for B38 blocking the interaction between COVID-19  
177 virus RBD and ACE2, the complex structures of COVID-19 virus RBD/B38-Fab and  
178 COVID-19 virus RBD/hACE2 were superimposed. Both the  $V_H$  and  $V_L$  of B38 result  
179 in steric hindrance to the RBD binding to ACE2 (Figure 4C). Notably, the RBDs in  
180 B38-bound form and hACE2-bound form exhibit no significant conformational  
181 changes with the  $C\alpha$  root mean squared deviation (RMSD) of 0.489 Å (for 194 atoms).  
182 Further analysis indicated that 18 of the 21 amino acids on RBD are identical in  
183 binding B38 and ACE2 (Figure 4D), which clearly explains why B38 completely  
184 abolish the binding between COVID-19 virus RBD and the receptor.  
185 COVID-19 virus and SARS-CoV RBDs share relatively high identity, and both of  
186 them bind to receptor ACE2 for entry. However, the binding affinities are different.  
187 COVID-19 virus RBD exhibits higher binding affinity for receptor binding because of  
188 more atomic interactions with hACE2 than that of SARS-CoV RBD. Consequently,  
189 the different amino acids located on the hACE2 binding interface may lead to the

190 generation of specific neutralizing antibodies in the host. So far, no antibody has been  
191 reported to cross-neutralize both SARS-CoV2 and SARS-CoV by competing the  
192 ACE2 binding site. CR3022 derived from a convalescent SARS patient can bind to  
193 RBDs from both viruses(18). However, it enables neutralizing SARS-CoV, but not  
194 COVID-19 virus. The epitope of CR3022 does not overlap with the ACE2-binding  
195 site(19), suggesting that it may be difficult to achieve cross-reactive neutralizing  
196 antibodies that can compete with ACE2 binding. A comprehensive understanding of  
197 the humoral immune responses against COVID-19 virus should be investigated in  
198 more patients. In addition, cocktail antibodies should be considered as an alternative  
199 therapeutic strategy to avoid potential escape mutants.

200 As the COVID-19 outbreak continues to spread, characterization of the epitopes on  
201 COVID-19 virus RBD protein is essential, which will provide valuable information to  
202 develop vaccines. Furthermore, the molecular features of the neutralizing antibodies  
203 targeting epitopes are helpful for the development of small molecule or peptide  
204 drugs/inhibitors. In conclusion, the neutralizing antibodies identified here are  
205 promising candidates for prophylactic and therapeutic treatment against COVID-19  
206 virus.

207

## 208 **References and notes**

- 209 1. N. Zhu *et al.*, A Novel Coronavirus from Patients with Pneumonia in China,  
210 2019. *N Engl J Med*, (2020).
- 211 2. C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak  
212 of global health concern. *Lancet* **395**, 470-473 (2020).
- 213 3. P. Zhou, Yang, X.L., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B.,

- 214 Chen, J., Luo, H., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R.,  
215 Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Yan, B., Wang, Y.Y.,  
216 Xiao, G.F., Shi, Z.L., A pneumonia outbreak associated with a new  
217 coronavirus of probable bat origin. *Nature*, (2020).
- 218 4. W. Tan *et al.*, Notes from the Field: A novel coronavirus genome identified in  
219 a cluster of pneumonia cases-Wuhan, China 2019-2020. *China CDC weekly* **2**,  
220 2 (2020).
- 221 5. R. Lu *et al.*, Genomic characterisation and epidemiology of 2019 novel  
222 coronavirus: implications for virus origins and receptor binding. *Lancet* **395**,  
223 565-574 (2020).
- 224 6. J. F. Chan *et al.*, A familial cluster of pneumonia associated with the 2019  
225 novel coronavirus indicating person-to-person transmission: a study of a  
226 family cluster. *Lancet* **395**, 514-523 (2020).
- 227 7. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in  
228 China. *Nature* **579**, 265-269 (2020).
- 229 8. G. Lu, Q. Wang, G. F. Gao, Bat-to-human: spike features determining 'host  
230 jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends*  
231 *Microbiol* **23**, 468-478 (2015).
- 232 9. D. M. Knipe, P. M. Howley, *Fields virology*. (Wolters Kluwer/Lippincott  
233 Williams & Wilkins Health, Philadelphia, PA, ed. 6th, 2013), pp. 2 volumes.
- 234 10. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2  
235 Spike Glycoprotein. *Cell*, (2020).
- 236 11. M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and  
237 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*,  
238 (2020).
- 239 12. Q. Wang *et al.*, Structural and Functional Basis of SARS-CoV-2 Entry by  
240 Using Human ACE2. *Cell*, (2020).
- 241 13. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion  
242 conformation. *Science* **367**, 1260-1263 (2020).
- 243 14. Y. Zhou, Y. Yang, J. Huang, S. Jiang, L. Du, Advances in MERS-CoV

- 244 Vaccines and Therapeutics Based on the Receptor-Binding Domain. *Viruses* **11**,  
245 (2019).
- 246 15. L. Du *et al.*, MERS-CoV spike protein: a key target for antivirals. *Expert Opin*  
247 *Ther Targets* **21**, 131-143 (2017).
- 248 16. L. Du *et al.*, The spike protein of SARS-CoV--a target for vaccine and  
249 therapeutic development. *Nat Rev. Microbiol* **7**, 226-236 (2009).
- 250 17. Q. Wang *et al.*, Neutralization mechanism of human monoclonal antibodies  
251 against Rift Valley fever virus. *Nat Microbiol* **4**, 1231-1241 (2019).
- 252 18. X. Tian *et al.*, Potent binding of 2019 novel coronavirus spike protein by a  
253 SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes &*  
254 *Infect* **9**, 382-385 (2020).
- 255 19. M. Yuan *et al.*, A highly conserved cryptic epitope in the receptor-binding  
256 domains of SARS-CoV-2 and SARS-CoV. *Science*, (2020).
- 257 20. Q. Wang *et al.*, Neutralization mechanism of human monoclonal antibodies  
258 against Rift Valley fever virus. *Nat Microbiol* **4**, 1231-1241 (2019).
- 259 21. Z. Otwinowski, Minor, W. & Charles W. Carter, Jr. , Processing of X-ray  
260 diffraction data collected in oscillation mode. *Methods Enzymol* **276**, 307-326  
261 (1997).
- 262 22. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics.  
263 *Acta Crystallogr D Biol Crystallogr* **60**, 2126-2132 (2004).
- 264 23. P. D. Adams *et al.*, PHENIX: building new software for automated  
265 crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*  
266 **58**, 1948-1954 (2002).
- 267 24. C. J. Williams *et al.*, MolProbity: More and better reference data for improved  
268 all-atom structure validation. *Protein Sci* **27**, 293-315 (2018).

269

## 270 **Materials and Methods**

## 271 **Ethics statement**

272 All procedures in this study involving authentic COVID-19 virus were performed in  
273 biosafety level 3 (BSL-3) facility. Murine studies were performed in an animal  
274 biosafety level 3 (ABSL-3) facility. All the procedures in the murine study were  
275 reviewed and approved by the Laboratory Animal Welfare and Ethics Committee in  
276 Chinese Academy of Sciences. The donor provided written informed consent for the  
277 use of blood and blood components followed the approval from the Research Ethics  
278 Committee of ShenZhen Third People's Hospital, China.

### 279 **Cells and Viruses**

280 HEK293T (ATCC CRL-3216) cells and Vero (ATCC CCL-81<sup>TM</sup>) cells were cultured  
281 at 37 °C with 5% CO<sub>2</sub> in Dulbecco's Modified Eagle medium (DMEM) supplemented  
282 with 10% fetal bovine serum (FBS). COVID-19 virus strain  
283 BetaCoV/shenzhen/SZTH-003/2020 (GISAID ID: EPI\_ISL\_406594) used in  
284 neutralization assay was isolated from the patient in Shenzhen Key Laboratory of  
285 Pathogen and Immunity, Shenzhen Third Peoples' Hospital. COVID-19 virus strain  
286 HB-01 used in the animal experiment was provided by Professor Wenjie Tan from  
287 Chinese center for disease control and prevention. Vero E6 cells were applied to the  
288 amplification and titer titration of the virus stocks.

### 289 **Gene construction**

290 The recombinant protein COVID-19 virus RBD was constructed into two vectors.  
291 Residues 331-532 (accession number EPI\_ISL\_402119) were cloned into pET21a for  
292 isolating mAbs as a bait. The coding sequences of COVID-19 RBD (residues 331-532),

293 SARS-CoV RBD (residues 306-527, accession number NC\_004718), and hACE2  
294 (residues 19-615, accession number BAJ21180) were used in assays of SPR, BLI and  
295 crystal screening were constructed into pFastBac1 plasmid with an N-terminal gp67  
296 signal peptide and a C-terminal six histidine tag. The pEGFP-N1-hACE2 plasmid was  
297 constructed by cloning the coding region into pEGFP-N1 vector using restriction  
298 enzymes XhoI and SmaI.

### 299 **Protein expression and purification**

300 The COVID-19 virus RBD recombinant protein was expressed in *E.coli* as inclusion  
301 body and in Bac-to-Bac expression system as soluble protein, respectively. The  
302 inclusion body was refolded and further purified by Superdex 200 Hiload 16/60  
303 column (GE Healthcare) in 20 mM Tris, pH 9.0, 150 mM NaCl. Human ACE2 protein  
304 was expressed in baculovirus expression system. The constructed pFastBac1 plasmids  
305 were transformed into DH10Bac competent cells to generate recombinant bacmids.  
306 The bacmids were transfected into sf9 cells to generate virus and then amplified the  
307 virus and infected High five cells for protein expression. Both the soluble COVID-19  
308 virus RBD and hACE2 were purified by HisTrap HP column (GE Healthcare) and  
309 were further purified by size-exclusion chromatography with a Superdex 200 column  
310 (GE Healthcare) in 20 mM Tris, pH 8.0, 150 mM NaCl.

311 The plasmids of B38 heavy chain and light chain were co-transfected into HEK293T  
312 cells to produce B38 IgG. The full-length of B38 were used in neutralization and  
313 animal experiments. B38 Fab were generated by papain digestion and further purified  
314 by Protein A column (GE Healthcare) as described before(20).

315 **Bio-Layer Interferometry (BLI)**

316 The antibody binding screening and the competitive binding of mAbs and hACE2 (or  
317 between two antibodies) were measured by BLI using the Octet RED96 system  
318 (FortéBio). All experiments were performed at 25°C, and the biosensors were  
319 pre-equilibrated in a buffer containing 20 mM HEPES, pH7.4 and 150 mM NaCl and  
320 0.005% (v/v) Tween-20 for 10min. For the antibody binding screening assay, 293T  
321 cell derived antibodies supernatants were loaded onto AHC biosensors for 120 s and  
322 flowed with 500 nM COVID-19 virus RBD or 1µM SARS-CoV RBD. To determine  
323 the competitive characteristics, 10 µg/mL biotinylated COVID-19 virus RBD was  
324 loaded onto streptavidin biosensors for 60 s, and flowed 300 nM of the first protein  
325 (one antibody) for 240 s and the second protein (hACE2 or the second antibody) for  
326 240 s. The interference patterns from the biotinylated RBD with buffer and the  
327 uncoated biosensors with protein were analyzed as two sets of controls. We used  
328 corrected data to compare the competitive characteristics by Octet data analysis  
329 software.

330 **Surface plasmon resonance (SPR)**

331 The affinity between COVID-19 virus RBD and antibodies were measured at room  
332 temperature using a BIAcore 8K system. All proteins used for kinetic analysis were  
333 exchanged to the buffer of 20 mM HEPES, 150 mM NaCl, pH 7.4 and 0.005% (v/v)  
334 Tween-20. A CM5 chip (GE Healthcare) was coupled with anti-human Fc antibody to  
335 capture the antibodies at 8000 response units. Gradient concentrations of COVID-19  
336 virus RBD (from 200 nM to 12.5 nM with 2-fold dilution) were then flowed over the

337 chip surface. After each cycle, the sensor surface was regenerated with Gly-HCl  
338 pH1.7. The affinity was calculated with BIAevaluation software.

### 339 **Crystal screening and structure determination**

340 The COVID-19 virus RBD protein and B38-Fab fragment were mixed at a molar  
341 ration of 1:1.2. The mixture was incubated on ice for 60 min and further purified by  
342 Superdex-200 column (GE Healthcare). 5 mg/mL and 10 mg/mL of hCoV-19  
343 RBD/B38 Fab proteins were used for crystal screening by vapor-diffusion sitting-drop  
344 method at 18°C. Diffracting crystals were obtained in the condition consisting of 0.15  
345 M ammonium sulfate, 0.1 M MES pH 6 and 15% w/v PEG 400. Diffraction data were  
346 collected at Shanghai Synchrotron Radiation Facility (SSRF) BL17U (wavelength,  
347 0.97919 Å). The crystals were cryo-protected by briefly soaking in reservoir solution  
348 supplemented with 20% (v/v) glycerol before flash-cooling in liquid nitrogen. The  
349 dataset was processed with HKL2000 software(21). The complex structure was  
350 determined by the molecular replacement method using Phaser with our previously  
351 reported hCoV-2 RBD structure (PDB code, 6LZG) and Fab structure (PDB code,  
352 4TSA). The atomic models were completed with Coot(22) and refined with  
353 phenix.refine in Phenix(23), and the stereochemical qualities of the final models were  
354 assessed with MolProbity(24). Data collection, processing, and refinement statistics  
355 are summarized in Table S1. All the figures were prepared with Pymol software  
356 (<http://www.pymol.org>).

### 357 **Neutralization assay**

358  $10^4$  Vero cells were seeded in a 96-well plate (Costar) per well 24 hours before



359 infection. On the day of infection, the cells were washed twice with PBS. Each mAb  
360 was diluted 2-fold in cell culture medium (modified eagle medium). 40  $\mu$ L of diluted  
361 mAb (100  $\mu$ g/mL as initial concentration) was added to 40  $\mu$ L of cell culture medium  
362 containing 100 times the tissue culture infective dose (TCID<sub>50</sub>) of the  
363 BetaCoV/Shenzhen/SZTH-003/2020 strain virus on a 96-well plate in decuplicate and  
364 incubated at 37 °C for 2 hours. The mixture was then added to cells and incubated at  
365 37 °C. The cytopathic effect was examined for 5 days post-infection. The complete  
366 absence of cytopathic effect in an individual culture well was defined as protection.  
367 The values of IC<sub>50</sub> were calculated using prism software (GraphPad).

#### 368 **Animal experiments**

369 Twelve female hACE2 transgenic mice (5-6 weeks old) were divided into three  
370 groups with four mice in each group. All the mice were anaesthetized with  
371 thibromoethanol and then intranasally inoculated with 50 $\mu$ L 1\*10<sup>5</sup> TCID<sub>50</sub>/mL  
372 COVID-19 virus (HB-01). After 12 hours, mice received a dose of 25 mg/kg B38 or  
373 H4 i.p. in a volume of 100  $\mu$ L, an equivalent volume of PBS was administered as a  
374 control. Body weights were monitored and recorded for four days. All the mice were  
375 euthanized at 3 dpi. The lung homogenates were prepared in 1 mL DMEM and then  
376 centrifuged at 3000 rpm for 10 min at 4 °C. The supernatant was collected to extract  
377 viral RNA by using the QIAamp Viral RNA Mini Kit (Qiagen). RNA was eluted in 80  
378  $\mu$ L elution buffer, and 5  $\mu$ L was taken as the template for the quantitative real-time  
379 reverse transcription-PCR (qRT-PCR) by rRT-PCR kit (Mabsky Biotech Co., Ltd.,  
380 CONFORMITE EUROPEENNE NO. DE/CA20/IVD-luxuslebenswelt-68/20). The

381 primers targeting N gene were used as followed: F:  
382 5'-ATTGGCATGGAAGTCACACCTTC-3', R:  
383 5'-TGCTTATTCAGCAAAATGACTTGAT-3', probe:  
384 FAM--TGGTTGACCTACACAGGTGCCATCA--BHQ1. The amplification was  
385 performed as followed steps: 50 °C for 30 min, 95 °C for 3 min, followed by 45 cycles  
386 at 95 °C 5 s and 55 °C for 30 s. This mice model was established and supplied by  
387 Institute for Laboratory Animal Resources, NIFDC.

388

### 389 **Acknowledgements**

390 We thank the staff of the BL17U1 beamline at Shanghai Synchrotron Radiation  
391 Facility (SSRF) for data collection. This work was supported by Zhejiang University  
392 special scientific research fund for COVID-19 prevention and control  
393 (2020XGZX019), the National Science and Technology Major Project  
394 (2018ZX10733403), the National Key R&D Program of China (2018YFC1200603),  
395 the National Key Plan for Scientific Research and Development of China  
396 (2016YFD0500304), National Natural Science Foundation of China (31872745 and  
397 81902058), and the National Science and Technology Major Projects of Infectious  
398 Disease Funds (2017ZX10304402).

### 399 **Author contributions**

400 Y.W., F.G., G.F.G. and L.L. initiated and coordinated the project. Y.W., F.G. and  
401 G.F.G designed the experiments. Y.L. and L.L. provided the convalescent PBMCs.  
402 Y.W. and C.S performed the cell sorting. W.P., C.Z, Z.L. and C.G.S. sequenced and  
403 constructed the antibodies. Y.W. conducted the SPR and Octet analysis with the help

404 of F.Z., F.W., Z.L. and Q.W.. C.S. and Y.Y. evaluated the neutralizing potency. S.L.  
405 and Y.B. conducted the animal experiments with the help from G.W., W.T., X.L. C.F.  
406 and H.X.. qRT-PCR was conducted by Y.G.. F.W., W.P. D.L. C.Z. and Z.L expressed  
407 and purified proteins. J.Q. and F.G. collected the diffraction data and determined the  
408 complex structure. Y.W., F.G. and G.F.G. analyzed the data and wrote the manuscript.  
409 S.T. revised the manuscript.

#### 410 **Competing interests**

411 Y.W., F.W., C.S., D.L., S.T., Y.L, G.F.G and L.L. are listed as inventors on pending  
412 patent applications for mAb B38 and H4. The other authors declare that they have no  
413 competing interests.

#### 414 **Data availability statements**

415 All the data and reagents presented in this study are available from the corresponding  
416 authors upon request.

#### 417 **Figure legends**

#### 418 **Figure 1. Characterization of COVID-19 virus specific neutralizing antibodies.**

419 (A-D) The binding kinetics of the four antibodies (B38, H4 B5 and H2) with  
420 COVID-19 virus RBD were measured by using a single-cycle BIAcore 8K system.  
421 The antibodies were captured on a CM5 chip coupled with anti-human Fc antibody.  
422 The COVID-19 RBD was serially diluted and injected with single-cycle kinetics  
423 procedure. The binding affinity (Kd) was labeled accordingly. (E-H) Competition  
424 binding to the COVID-19 virus RBD between antibody and ACE2 was measured by  
425 BLI in OctetRed96. Biotinylated COVID-19 virus RBD (10 µg/mL) were

426 immobilized on SA sensors. The SA sensors were saturated with antibodies, and then  
427 flowed with corresponding antibody in the presence of 300 nM soluble ACE2 (blue)  
428 or without ACE2 (red). As a control, the immobilized biotinylated COVID-19 virus  
429 RBD was first flowed with buffer, and then flowed with the equal molar of ACE2  
430 (black). (I) hACE2-EGFP was expressed on the HEK293T cell surface, and the cells  
431 were stained with 200 ng/mL COVID-19 virus RBD his-tag proteins pre-incubated  
432 with isotype IgG, B38, H4, B5 or H2. The percentage of both anti-histag APC<sup>+</sup> and  
433 EGFP<sup>+</sup> cells were calculated. (J-K) Competition binding to COVID-19 virus RBD  
434 between B38 and H4 was measured by BLI. Immobilized COVID-19 virus RBD (10  
435 µg/mL) were saturated with 300 nM of the first antibody, and then flowed with equal  
436 molar of the first antibody in the presence of (blue) or without (red) the second  
437 antibody. As a control, the immobilized COVID-19 RBD was first flowed with buffer,  
438 and then flowed with the second antibody (black).

439 **Figure 2. Four antibodies can effectively neutralize COVID-19 virus.** The  
440 mixtures of SARS-CoV-2 and serially diluted antibodies were added to Vero E6 cells.  
441 After 5 days incubation, IC<sub>50</sub> were calculated by fitting the CPE from serially diluted  
442 antibody to a sigmoidal dose-response curve. The IC<sub>50</sub> were labeled accordingly.

443 **Figure 3. The protection efficiency of mAbs in hACE2 mice model post infection**  
444 **with COVID-19 virus.** (A) Body weight loss were recorded for PBS (n=4), B38  
445 treatment (n=4) and H4 treatment (n=4) groups. All the mice were challenged  
446 intranasally with COVID-19 virus, and 25 mg/kg antibodies were injected (i.p.) 12  
447 hours post-infection. Equal volume of PBS was used as a control. The weight loss

448 was recorded over three days, and the significant difference can be observed between  
449 B38 group and PBS group (unpaired *t*-test, \*\*\**p*<0.001). (B) The virus titer in lungs  
450 of three groups were determined at 3 dpi by qRT-PCR. The mAb treatment group can  
451 reduce the viral load in the lung of mice (unpaired *t*-test, \*\*\**p*<0.001).

452 **Figure 4. Structural analysis of B38 and COVID-19 virus RBD complex and the**  
453 **epitope comparison between B38 and hACE2.** (A) The overall structure of B38 Fab  
454 and COVID-19 virus RBD complex. The B38 heavy chain (cyan), light chain (green)  
455 and COVID-19 virus RBD (magenta) are displayed in cartoon representation. (B) The  
456 epitope of B38 are shown in surface representation. The contacted residues by heavy  
457 chain, light chain or both are colored in cyan, green and magenta, respectively. The  
458 identical residues on RBD involved in binding to both B38 and hACE2 are labeled in  
459 red. (C) Superimposition of B38/COVID-19 virus RBD and hACE2/COVID-19 virus  
460 RBD (PDB: 6LZG). All the molecules are presented in cartoon, with the same colors  
461 in panel A. hACE2 is colored in light pink. (D) The residues involved in hACE2-RBD  
462 binding are highlighted in light pink. The identical residues on RBD involved in  
463 binding to both B38 and hACE2 are labeled in red. (E) The complex structure of  
464 SARS-CoV RBD (light blue) and hACE2 (yellow) (PDB:2AJF). (F) The residues of  
465 SARS-CoV RBD in contact with hACE2 are colored in yellow. The residues are  
466 numbered according to SARS-CoV RBD. The identical residues involved in hACE2  
467 binding of two RBDs are labeled in red. (G-I) The detailed interactions between  
468 COVID-19 virus RBD and HCDR loops. (J-K) The detailed interactions between  
469 COVID-19 virus RBD and LCDR loops. The residues are shown in sticks with the

470 identical colors to figure 3C. The water molecules are displayed in red sphere.









